GSK's Velzatinib Receives Japan Orphan Drug Designation for GIST
GSK’s investigational KIT inhibitor velzatinib received Orphan Drug Designation in Japan for GIST, supported by Phase 1/1b data and phase 3 trials are underway, with second-line results expected in 2027.
Investigational Drug Velzatinib | 20/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy